US Approvals Analysis: Original PMA Slowdown, De Novo Upswing Among Recent Trends
Executive Summary
The volume of original PMAs coming to US FDA for review is down recently, while panel-track supplement, de novo and 510(k) volumes are up. October, meanwhile, was a relatively light month for novel device approvals, but better-than-average for 510(k) clearances.
You may also be interested in...
Acutus Is Trying To Fundamentally Change Understanding Of Arrhythmia With AcQMap
New trial results show Acutus Medical's AcQMap platform has the ability to classify conduction patterns and localized non-pulmonary-vein therapeutic targets for ablation to treat atrial fibrillation, which could have implications for both treatment of atrial fibrillation and understanding the genetic markers for this common arrhythmia, according to the authors.
DEVICE DEBUTS: Product And New Indication Launches From Medtronic, Strkyer, Siemens, And More
This month's edition of Device Debuts includes new product launches from Medtronic, Cochlear, Qualcomm, Titan Spine, Stryker, Philips, Nuance, Nevro, Siemens, Vortex BioSciences, ResMed, Respircardia, and others.
'Refuse-To-Accept' Policy Outlined For De Novos In New US FDA Draft Guidance
Following a user fee deal that will subject de novo applications to performance goals and user-fee payments, US FDA has proposed a guidance that attempts to explain its process for considering when to accept, and when not to accept, a de novo submission for review.